Reel­ing from PhII flop, Cy­tomX lays off 40% as ex­ecs go back to draw­ing board, seek new deals

Just days af­ter putting a lead drug on the back­burn­er in the wake of a Phase II flop, Cy­tomX has set­tled on a makeover plan.

The South San Fran­cis­co biotech is lay­ing off around 40% of its staffers as part of a re­vamp in­tend­ed to pri­or­i­tize in­ter­nal work on its pre­clin­i­cal and ear­ly clin­i­cal pipeline — hit­ting hard­est on the de­vel­op­ment and gen­er­al and ad­min­is­tra­tive teams. At the end of 2021, Cy­tomX re­port­ed it had 174 full-time em­ploy­ees.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER